Phibro Animal Health Corporation
NASDAQ:PAHCDrug Manufacturers - Specialty & Generic
+$0.38 today
- Market cap
- $1.44B
- Beta
- 0.46
- P/E (TTM)
- 13.3
- EPS (TTM)
- $2.35
- Dividend yield
- 1.54%
Volume 0.11M
Average 0.37M
PAHC EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Phibro Animal Health CorporationNASDAQ: PAHC
EBITDA · Q3 FY2026 · quarter ended Mar 2026
EBITDA grows, but more slowly than its trailing trend
Q3 FY2026 EBITDA of $55.64M rose 8.3% year over year, behind the +80.1% change in trailing-twelve-month EBITDA. Sequentially, it fell 10.8% from the prior quarter. Over 3 fiscal years it compounded at +7.8% a year.
Context
- EBITDA amounted to 11.3% of revenue in FY2025, up 4.5 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of $258.4M (+76.0%) for the fiscal year ending Jun 2026, a slowdown from the +112.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $55.64M-10.8% QoQ
- Last fiscal yearJun 2025
- $146.85M+112.6% YoY
- LTMMar 2026
- $225.31M+80.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +8.3% | +35.3% | +27.0 pp |
| 1 year | +112.6% | +76.0% | -36.7 pp |
| 3-year CAGR | +7.8% | +25.8% | +18.0 pp |
| 5-year CAGR | +18.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 146.85M USD
- Year-over-year change
- +112.6%
- 4-year CAGR
- +7.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 146.85M | +112.6% |
| FY2024 | 2024-06-30 | 69.06M | -34.9% |
| FY2023 | 2023-06-30 | 106.03M | -9.5% |
| FY2022 | 2022-06-30 | 117.13M | +6.3% |
| FY2021 | 2021-06-30 | 110.21M | — |
EBITDA vs competitors
How PAHC compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +80.1% is the 2nd highest of 6, against a peer median of -23.8%.
- EBITDA amounts to 15.0% of revenue for PAHC, versus a peer median of 21.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $13.93B USD | -44.4% | +9.9% | 21.0% | |
| LTM Jun 2026 | $3.99B USD | -1.1% | +6.6% | 42.0% | |
| LTM Sep 2026 | $679M USD | -23.8% | -7.9% | 13.2% | |
| LTM Mar 2026 | $225.31M USD | +80.1% | +7.8% | 15.0% | |
| LTM Aug 2026 | $105.13M USD | +112.0% | +9.9% | 11.9% | |
| FY2025 | -CN¥42.52M CNY | -199.8% | — | 36.5% | |
| Peer median (excluding PAHC) | — | -23.8% | +8.2% | 21.0% | |
Competitors are the stored peer set for PAHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 833.35M | 942.26M | 977.89M | 1.02B | 1.3B |
| Cost of Revenue | 561.97M | 656.86M | 679.65M | 704.59M | 896.27M |
| Gross Profit | 271.38M | 285.4M | 298.24M | 313.09M | 399.94M |
| Gross Margin | 32.6% | 30.3% | 30.5% | 30.8% | 30.9% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 196.51M | 206.41M | 226.39M | 259.78M | 289.48M |
| Operating Expenses | 196.51M | 206.41M | 226.39M | 259.78M | 289.48M |
| Depreciation & Amortization | 31.88M | 32.71M | 34.01M | 36.18M | 45.61M |
| EBITDA | 110.21M | 117.13M | 106.03M | 69.06M | 146.85M |
| EBITDA Margin | 13.2% | 12.4% | 10.8% | 6.8% | 11.3% |
| Operating Income | 74.87M | 78.99M | 71.85M | 53.32M | 110.47M |
| Operating Margin | 9.0% | 8.4% | 7.3% | 5.2% | 8.5% |
| Interest Income | 838K | 816K | 3.36M | 4.47M | 2.62M |
| Interest Expense | 10.4M | 12.1M | 17.95M | 21.97M | 33.25M |
| Other Income / Expenses | (8.4M) | (6.66M) | (17.78M) | (42.4M) | (42.47M) |
| Income Before Tax | 66.47M | 72.33M | 54.07M | 10.92M | 67.99M |
| Pre-Tax Margin | 8.0% | 7.7% | 5.5% | 1.1% | 5.2% |
| Income Tax Expense | 12.08M | 23.15M | 21.47M | 8.5M | 19.73M |
| Net Income | 54.39M | 49.18M | 32.61M | 2.42M | 48.26M |
| Net Margin | 6.5% | 5.2% | 3.3% | 0.2% | 3.7% |
| EPS (Basic) | 1.34 | 1.21 | 0.81 | 0.06 | 1.19 |
| EPS (Diluted) | 1.34 | 1.21 | 0.81 | 0.06 | 1.19 |
| Weighted Avg Shares | 40.5M | 40.5M | 40.5M | 40.5M | 40.5M |
| Weighted Avg Shares (Diluted) | 40.5M | 40.5M | 40.5M | 40.52M | 40.7M |
Phibro Animal Health Corporation
NASDAQ:PAHC
Intrinsic Alpha fair value
Locked
Current Price
$35.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.